EUVIMEDEUVIMED entdecken
Leitlinie

Challenges in periodic revision of genetic testing results: Comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 variants of uncertain significance

Tiago Finger Andreis, Kayana Isabel Weber de Souza, Igor Araujo Vieira, Bárbara Alemar, Marialva Sinigaglia, Yasminne Marinho de Araújo Rocha, Osvaldo Artigalás, Camila Bittar, Cristina Brinckmann Oliveira Netto, Patricia Ashton-Prolla, Clévia Rosset

Gene · 2023

DOI: 10.1016/j.gene.2023.147281 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Gene, 2023. Verfasst von Tiago Finger Andreis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Braz…. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of cancer predisposition syndromes, it is widely known that the correct interpretation of germline variants identified in multigene panel testing is essential for adequate genetic counseling and clinical decision making, in which variants of uncertain significance (VUS) are not considered actionable findings. Thus, their periodic re-evaluation using appropriate guidelines is notably important. In the present study, we compared the performance of the main variant classification guidelines (ACMG, Sherloc and ENIGMA) in variant reassessment, using as input a BRCA1/2 VUS case series (retrospective analysis) from Brazil, an ethnically diverse and admixed country with substantial challenges in VUS reclassification. As main findings, two of the 15 VUS analyzed were reclassified as likely pathogenic by the 3 guidelines, BRCA1 c.4987-3C > G (rs397509213) and BRCA2 c.7868A > G (rs80359012). Moreover, challenges in variant classification and reassessment are described and additional in silico data about structural impact of the variant BRCA2 c.7868A > G are provided. We hypothesize that the establishment of a framework to reassess VUS could improve this process in health centers that have not yet implemented this practice. Results of this study underscore that periodic monitoring of the functional, clinical, and bioinformatics data of a VUS by a multidisciplinary team are of utmost importance in clinical practice. When there is a specific guideline for a given gene, such as ENIGMA for BRCA1/2, it should be considered the first option for variant assessment. Finally, recruitment of VUS carriers and their relatives to participate in variant segregation studies and publication of VUS reclassification results in the international scientific literature should be encouraged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseBreast NeoplasmsHumansFemaleRetrospective StudiesGenetic TestingBRCA2 ProteinGenetic CounselingSyndromeBRCA1 Protein

Stichwörter der Autor:innen

BRCA1BRCA2Brazilian populationGenetic testing resultsVariant classification guidelinesVariant of uncertain significanceVariant reassessment

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Genética e Biologia Molecular (PPGBM)…
  • Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil; Programa de Pós-Graduação em Ciências Médicas: Medicina (PPGCM), U…
  • Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil; Escola de Saúde, Universidade do Vale do Rio dos Sinos (UNISINOS),…
  • Laboratório de Medicina Genômica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil.
  • Instituto do Câncer Infantil (ICI),Porto Alegre, Rio Grande do Sul, Brazil.
  • Hospital Moinhos de Vento (HMV), Porto Alegre, Rio Grande do Sul, Brazil.

Zitieren

APA

Andreis, T. F., de Souza, K. I. W., Vieira, I. A., Alemar, B., Sinigaglia, M., de Araújo Rocha, Y. M., Artigalás, O., Bittar, C., Oliveira Netto, C. B., Ashton-Prolla, P., & Rosset, C. (2023). Challenges in periodic revision of genetic testing results: Comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 variants of uncertain significance. Gene. https://doi.org/10.1016/j.gene.2023.147281

Vancouver

Andreis TF, de Souza KIW, Vieira IA, Alemar B, Sinigaglia M, de Araújo Rocha YM, et al. Challenges in periodic revision of genetic testing results: Comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 variants of uncertain significance. Gene. 2023. doi:10.1016/j.gene.2023.147281

BibTeX
@article{Andreis2023,
  author = {Andreis, Tiago Finger and de Souza, Kayana Isabel Weber and Vieira, Igor Araujo and Alemar, Bárbara and Sinigaglia, Marialva and de Araújo Rocha, Yasminne Marinho and Artigalás, Osvaldo and Bittar, Camila and Oliveira Netto, Cristina Brinckmann and Ashton-Prolla, Patricia and Rosset, Clévia},
  title = {Challenges in periodic revision of genetic testing results: Comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 variants of uncertain significance},
  journal = {Gene},
  year = {2023},
  doi = {10.1016/j.gene.2023.147281}
}
Kostenlos starten →